middle.news
Mayne Pharma Doubles EBITDA on 5% Revenue Growth, Eyes US Dermatology Expansion
3:58am on Saturday 30th of August, 2025 AEST
•
Healthcare
Read Story
Mayne Pharma Doubles EBITDA on 5% Revenue Growth, Eyes US Dermatology Expansion
3:58am on Saturday 30th of August, 2025 AEST
Key Points
5% revenue growth to $408.1 million with 13% gross profit increase
Underlying EBITDA surged 105% to $47 million
Women’s Health segment revenue up 25%, led by NEXTSTELLIS®
Dermatology revenue declined 12% but gross margins improved
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Mayne Pharma (ASX:MYX)
OPEN ARTICLE